Skip to main content
Erschienen in: Heart Failure Reviews 3/2023

22.11.2021 | Heart Failure

Prognostic impact of diabetes in chronic and acute heart failure

verfasst von: Stefano Ghio, Valentina Mercurio, Andrea Attanasio, Gaetano Asile, Carlo Gabriele Tocchetti, Stefania Paolillo

Erschienen in: Heart Failure Reviews | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

A strong, bidirectional relationship exists between diabetes mellitus (DM) and heart failure (HF) and DM is responsible of the activation of several molecular and pathophysiological mechanisms that may, on the long term, damage the heart. However, the prognostic role of DM in the context of chronic and acute HF is still not yet defined and there are several gaps of evidence in the literature on this topic. These gaps are related to the wide phenotypic heterogeneity of patients with chronic and acute HF and to the concept that not all diabetic patients are the same, but there is the necessity to better characterize the disease and each single patient, also considering the role of other possible comorbidities. The aim of the present review is to summarize the pathophysiological mechanisms subtending the negative effect of DM in HF and analyze the available data exploring the prognostic impact of such comorbidity in both chronic and acute HF.
Literatur
1.
Zurück zum Zitat Bell DSH (2003) Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26:2433–2441PubMedCrossRef Bell DSH (2003) Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26:2433–2441PubMedCrossRef
2.
Zurück zum Zitat Aon MA, Tocchetti CG, Bhatt N, Paolocci N, Cortassa S (2015) Protective mechanisms of mitochondria and heart function in diabetes. Antioxid Redox Signal 22:1563–1586PubMedPubMedCentralCrossRef Aon MA, Tocchetti CG, Bhatt N, Paolocci N, Cortassa S (2015) Protective mechanisms of mitochondria and heart function in diabetes. Antioxid Redox Signal 22:1563–1586PubMedPubMedCentralCrossRef
3.
Zurück zum Zitat Boyer JK, Thanigaraj S, Schechtman KB, Pérez JE (2004) Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 93:870–875PubMedCrossRef Boyer JK, Thanigaraj S, Schechtman KB, Pérez JE (2004) Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 93:870–875PubMedCrossRef
4.
Zurück zum Zitat Carley AN, Severson DL (2005) Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids 1734:112–126CrossRef Carley AN, Severson DL (2005) Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids 1734:112–126CrossRef
5.
Zurück zum Zitat Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90:207–258PubMedCrossRef Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90:207–258PubMedCrossRef
6.
Zurück zum Zitat Hue L, Taegtmeyer H (2009) The Randle cycle revisited: a new head for an old hat. American Journal of Physiology - Endocrinology and Metabolism 297:E578–E591PubMedPubMedCentralCrossRef Hue L, Taegtmeyer H (2009) The Randle cycle revisited: a new head for an old hat. American Journal of Physiology - Endocrinology and Metabolism 297:E578–E591PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Harmancey R, Wilson CR, Taegtmeyer H (2008) Adaptation and maladaptation of the heart in obesity. Hypertension 52:181–187PubMedCrossRef Harmancey R, Wilson CR, Taegtmeyer H (2008) Adaptation and maladaptation of the heart in obesity. Hypertension 52:181–187PubMedCrossRef
8.
Zurück zum Zitat Tocchetti CG, Caceres V, Stanley BA et al (2012) GSH or palmitate preserves mitochondrial energetic/redox balance, preventing mechanical dysfunction in metabolically challenged myocytes/hearts from type 2 diabetic mice. Diabetes 61:3094–3105PubMedPubMedCentralCrossRef Tocchetti CG, Caceres V, Stanley BA et al (2012) GSH or palmitate preserves mitochondrial energetic/redox balance, preventing mechanical dysfunction in metabolically challenged myocytes/hearts from type 2 diabetic mice. Diabetes 61:3094–3105PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef
10.
Zurück zum Zitat Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625PubMedCrossRef Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625PubMedCrossRef
12.
Zurück zum Zitat Negre-Salvayre A, Salvayre R, Augé N, Pamplona R, Portero-Otín M (2009) Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal 11:3071–3109PubMedCrossRef Negre-Salvayre A, Salvayre R, Augé N, Pamplona R, Portero-Otín M (2009) Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal 11:3071–3109PubMedCrossRef
13.
Zurück zum Zitat Ussher JR, Jaswal JS, Lopaschuk GD (2012) Pyridine nucleotide regulation of cardiac intermediary metabolism. Circulation Res c111:628–641 Ussher JR, Jaswal JS, Lopaschuk GD (2012) Pyridine nucleotide regulation of cardiac intermediary metabolism. Circulation Res c111:628–641
14.
Zurück zum Zitat Anderson EJ, Lustig ME, Boyle KE et al (2009) Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 119:573–581PubMedPubMedCentralCrossRef Anderson EJ, Lustig ME, Boyle KE et al (2009) Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 119:573–581PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Burgoyne JR, Oka SI, Ale-Agha N, Eaton P (2013) Hydrogen peroxide sensing and signaling by protein kinases in the cardiovascular system. Antioxid Redox Signal 18:1042–1052PubMedPubMedCentralCrossRef Burgoyne JR, Oka SI, Ale-Agha N, Eaton P (2013) Hydrogen peroxide sensing and signaling by protein kinases in the cardiovascular system. Antioxid Redox Signal 18:1042–1052PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Harmancey R, Taegtmeyer H (2008) The complexities of diabetic cardiomyopathy: lessons from patients and animal models. Curr DiabRep 8:243–248 Harmancey R, Taegtmeyer H (2008) The complexities of diabetic cardiomyopathy: lessons from patients and animal models. Curr DiabRep 8:243–248
19.
Zurück zum Zitat Ishikawa T, Kajiwara H, Kurihara S (1999) Alterations in contractile properties and Ca2+ handling in streptozotocin-induced diabetic rat myocardium. Am J Physiol - Hear Circ Physiol 277:H2185–H2194CrossRef Ishikawa T, Kajiwara H, Kurihara S (1999) Alterations in contractile properties and Ca2+ handling in streptozotocin-induced diabetic rat myocardium. Am J Physiol - Hear Circ Physiol 277:H2185–H2194CrossRef
20.
Zurück zum Zitat Netticadan T, Temsah RM, Kent A, Elimban V, Dhalla NS (2001) Depressed levels of Ca2+-cycling proteins may underlie sarcoplasmic reticulum dysfunction in the diabetic heart. Diabetes 50:2133–2138PubMedCrossRef Netticadan T, Temsah RM, Kent A, Elimban V, Dhalla NS (2001) Depressed levels of Ca2+-cycling proteins may underlie sarcoplasmic reticulum dysfunction in the diabetic heart. Diabetes 50:2133–2138PubMedCrossRef
21.
Zurück zum Zitat Louch WE, Stokke MK, Sjaastad I, Christensen G, Sejersted OM (2012) No rest for the weary: diastolic calcium homeostasis in the normal and failing myocardium. Physiology 27:308–323PubMedCrossRef Louch WE, Stokke MK, Sjaastad I, Christensen G, Sejersted OM (2012) No rest for the weary: diastolic calcium homeostasis in the normal and failing myocardium. Physiology 27:308–323PubMedCrossRef
22.
Zurück zum Zitat Bers DM (2006) Altered cardiac myocyte Ca regulation in heart failure. Physiology 21:380–387PubMedCrossRef Bers DM (2006) Altered cardiac myocyte Ca regulation in heart failure. Physiology 21:380–387PubMedCrossRef
23.
25.
Zurück zum Zitat Nickel A, Löffler J, Maack C (2013) Myocardial energetics in heart failure. Basic Res Cardiol 108:358PubMedCrossRef Nickel A, Löffler J, Maack C (2013) Myocardial energetics in heart failure. Basic Res Cardiol 108:358PubMedCrossRef
26.
Zurück zum Zitat Zhong Y, Ahmed S, Grupp IL, Matlib MA (2001) Altered SR protein expression associated with contractile dysfunction in diabetic rat hearts. Am J Physiol - Hear Circ Physiol 281:H1137–H1147CrossRef Zhong Y, Ahmed S, Grupp IL, Matlib MA (2001) Altered SR protein expression associated with contractile dysfunction in diabetic rat hearts. Am J Physiol - Hear Circ Physiol 281:H1137–H1147CrossRef
27.
Zurück zum Zitat Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, Dillmann WH (2002) Overexpression of the sarcoplasmic reticulum CA2+-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51:1166–1171PubMedCrossRef Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, Dillmann WH (2002) Overexpression of the sarcoplasmic reticulum CA2+-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 51:1166–1171PubMedCrossRef
28.
Zurück zum Zitat Vetter R, Rehfeld U, Reissfelder C et al (2002) Transgenic overexpression of the sarcoplasmic reticulum Ca2+ATPase improves reticular Ca2+ handling in normal and diabetic rat hearts. FASEB J 16:1657–1659PubMedCrossRef Vetter R, Rehfeld U, Reissfelder C et al (2002) Transgenic overexpression of the sarcoplasmic reticulum Ca2+ATPase improves reticular Ca2+ handling in normal and diabetic rat hearts. FASEB J 16:1657–1659PubMedCrossRef
29.
Zurück zum Zitat Francesco DR, Fabien D, Marc L et al (2013) Abstract 16277: hyperglycemia in congestive heart failure patients is associated to sympathetic overactivity (abstract). Circulation 128(suppl_22):A16277–A16277 Francesco DR, Fabien D, Marc L et al (2013) Abstract 16277: hyperglycemia in congestive heart failure patients is associated to sympathetic overactivity (abstract). Circulation 128(suppl_22):A16277–A16277
30.
Zurück zum Zitat Mebazaa A, Gayat E, Lassus J, Meas T, Mueller C, Maggioni A, Peacock F, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Tavazzi L, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Parenica J, Deye N, Boukef R, Collet C, Van den Berghe G, Cohen-Solal A, Januzzi JL Jr (2013) GREAT Network. Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol 61:820–829 Mebazaa A, Gayat E, Lassus J, Meas T, Mueller C, Maggioni A, Peacock F, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Tavazzi L, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Parenica J, Deye N, Boukef R, Collet C, Van den Berghe G, Cohen-Solal A, Januzzi JL Jr (2013) GREAT Network. Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol 61:820–829
31.
Zurück zum Zitat Seferović PM, Paulus WJ (2015) Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 36:1718–1727PubMedCrossRef Seferović PM, Paulus WJ (2015) Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 36:1718–1727PubMedCrossRef
32.
Zurück zum Zitat Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L (2006) EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 27:2725–2736 Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L (2006) EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 27:2725–2736
33.
Zurück zum Zitat Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW, Scientific Advisory Committee ADHERE, Investigators. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, (2002) to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2007(153):1021–1028 Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW, Scientific Advisory Committee ADHERE, Investigators. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, (2002) to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2007(153):1021–1028
34.
Zurück zum Zitat Dauriz M, Mantovani A, Bonapace S, Verlato G, Zoppini G, Bonora E, Targher G (2017) Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis. Diabetes Care 40:1597–1605PubMedCrossRef Dauriz M, Mantovani A, Bonapace S, Verlato G, Zoppini G, Bonora E, Targher G (2017) Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis. Diabetes Care 40:1597–1605PubMedCrossRef
35.
Zurück zum Zitat MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ (2008) CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29:1377–1385 MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ (2008) CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29:1377–1385
36.
Zurück zum Zitat Johansson I, Dahlstrom U, Edner M, Nasman P, Ryden L, Norhammar A (2016) Prognostic implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure. J Am Coll Cardiol 68:1404–1416PubMedCrossRef Johansson I, Dahlstrom U, Edner M, Nasman P, Ryden L, Norhammar A (2016) Prognostic implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure. J Am Coll Cardiol 68:1404–1416PubMedCrossRef
37.
Zurück zum Zitat Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR (2003) BEST Investigators. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 42:914–922 Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR (2003) BEST Investigators. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 42:914–922
38.
Zurück zum Zitat Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ (2001) Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 38:421–428PubMedCrossRef Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ (2001) Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 38:421–428PubMedCrossRef
39.
Zurück zum Zitat MacDonald MR, Jhund PS, Petrie MC, Lewsey JD, Hawkins NM, Bhagra S, Munoz N, Varyani F, Redpath A, Chalmers J, MacIntyre K, McMurray JJ (2008) Discordant short- and long-term outcomes associated with diabetes in patients with heart failure: importance of age and sex: a population study of 5.1 million people in Scotland. Circ Heart Fail 1:234–241 MacDonald MR, Jhund PS, Petrie MC, Lewsey JD, Hawkins NM, Bhagra S, Munoz N, Varyani F, Redpath A, Chalmers J, MacIntyre K, McMurray JJ (2008) Discordant short- and long-term outcomes associated with diabetes in patients with heart failure: importance of age and sex: a population study of 5.1 million people in Scotland. Circ Heart Fail 1:234–241
40.
Zurück zum Zitat Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M (2016) PARADIGM-HF Investigators and Committees. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI With ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 9:e002560 Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M (2016) PARADIGM-HF Investigators and Committees. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI With ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail 9:e002560
41.
Zurück zum Zitat Aune D, Schlesinger S, Neuenschwander M, Feng T, Janszky I, Norat T, Riboli E (2018) Diabetes mellitus, blood glucose and the risk of heart failure: a systematic review and meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis 28:1081–1091PubMedCrossRef Aune D, Schlesinger S, Neuenschwander M, Feng T, Janszky I, Norat T, Riboli E (2018) Diabetes mellitus, blood glucose and the risk of heart failure: a systematic review and meta-analysis of prospective studies. Nutr Metab Cardiovasc Dis 28:1081–1091PubMedCrossRef
42.
Zurück zum Zitat Pavlović A, Polovina M, Ristić A, Seferović JP, Veljić I, Simeunović D, Milinković I, Krljanac G, Ašanin M, Oštrić-Pavlović I, Seferović PM (2019) Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction. Eur J Prev Cardiol 26:72–82PubMedCrossRef Pavlović A, Polovina M, Ristić A, Seferović JP, Veljić I, Simeunović D, Milinković I, Krljanac G, Ašanin M, Oštrić-Pavlović I, Seferović PM (2019) Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction. Eur J Prev Cardiol 26:72–82PubMedCrossRef
43.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD et al (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891–975 Ponikowski P, Voors AA, Anker SD et al (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891–975
44.
Zurück zum Zitat Ghio S, Guazzi M, Scardovi AB, Klersy C, Clemenza F, Carluccio E, Temporelli PL, Rossi A, Faggiano P, Traversi E, Vriz O, Dini FL (2017) all investigators. Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction. Eur J Heart Fail 19:873–879 Ghio S, Guazzi M, Scardovi AB, Klersy C, Clemenza F, Carluccio E, Temporelli PL, Rossi A, Faggiano P, Traversi E, Vriz O, Dini FL (2017) all investigators. Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction. Eur J Heart Fail 19:873–879
45.
Zurück zum Zitat Ghio S, Klersy C, Carluccio E, Scardovi AB, Scelsi L, Falletta C, Rossi A, Faggiano P, Traversi E, Vriz O, Guazzi M, Dini FL, Targher G, Temporelli PL (2020) Pre-existing type 2 diabetes is associated with increased all-cause death independently of echocardiographic predictors of poor prognosis only in ischemic heart disease. Nutr Metab Cardiovasc Dis 30:2036–2040PubMedCrossRef Ghio S, Klersy C, Carluccio E, Scardovi AB, Scelsi L, Falletta C, Rossi A, Faggiano P, Traversi E, Vriz O, Guazzi M, Dini FL, Targher G, Temporelli PL (2020) Pre-existing type 2 diabetes is associated with increased all-cause death independently of echocardiographic predictors of poor prognosis only in ischemic heart disease. Nutr Metab Cardiovasc Dis 30:2036–2040PubMedCrossRef
46.
Zurück zum Zitat Dauriz M, Mantovani A, Bonapace S, Verlato G, Zoppini G, Bonora E et al (2017) Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis. Diabetes Care 40:1597–1605PubMedCrossRef Dauriz M, Mantovani A, Bonapace S, Verlato G, Zoppini G, Bonora E et al (2017) Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis. Diabetes Care 40:1597–1605PubMedCrossRef
47.
Zurück zum Zitat Paolillo S, Salvioni E, Perrone Filardi P et al (2020) MECKI score research group (see Appendix A). Long-term prognostic role of diabetes mellitus and glycemic control in heart failure patients with reduced ejection fraction: insights from the MECKI Score database. Int J Cardiol 317:103–110 Paolillo S, Salvioni E, Perrone Filardi P et al (2020) MECKI score research group (see Appendix A). Long-term prognostic role of diabetes mellitus and glycemic control in heart failure patients with reduced ejection fraction: insights from the MECKI Score database. Int J Cardiol 317:103–110
48.
Zurück zum Zitat Agostoni P, Paolillo S, Mapelli M et al (2018) Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison. Eur J Heart Fail 20:700–710PubMedCrossRef Agostoni P, Paolillo S, Mapelli M et al (2018) Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long-term comparison. Eur J Heart Fail 20:700–710PubMedCrossRef
49.
Zurück zum Zitat Kouwert IJ, Bakker EA, Cramer MJ, Snoek JA, Eijsvogels TM (2020) Comparison of MAGGIC and MECKI risk scores to predict mortality after cardiac rehabilitation among Dutch heart failure patients. Eur J Prev Cardiol 27:2126–2130PubMedCrossRef Kouwert IJ, Bakker EA, Cramer MJ, Snoek JA, Eijsvogels TM (2020) Comparison of MAGGIC and MECKI risk scores to predict mortality after cardiac rehabilitation among Dutch heart failure patients. Eur J Prev Cardiol 27:2126–2130PubMedCrossRef
50.
Zurück zum Zitat Chioncel O, Mebazaa A, Harjola VP et al (2017) Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19:1242–1254PubMedCrossRef Chioncel O, Mebazaa A, Harjola VP et al (2017) Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19:1242–1254PubMedCrossRef
51.
Zurück zum Zitat Teerlink JR, Felker GM, McMurray JJV et al (2016) Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study. J Am Coll Cardiol 67:1444–1455PubMedCrossRef Teerlink JR, Felker GM, McMurray JJV et al (2016) Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study. J Am Coll Cardiol 67:1444–1455PubMedCrossRef
52.
Zurück zum Zitat Teerlink JR, Cotter G, Davison BA et al (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381:29–39PubMedCrossRef Teerlink JR, Cotter G, Davison BA et al (2013) Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381:29–39PubMedCrossRef
53.
Zurück zum Zitat Targher G, Dauriz M, Tavazzi L et al (2016) Prognostic impact of in-hospital hyperglycemia in hospitalized patients with acute heart failure: results of the IN-HF (Italian Network on Heart Failure) Outcome registry. Int J Cardiol 203:587–593PubMedCrossRef Targher G, Dauriz M, Tavazzi L et al (2016) Prognostic impact of in-hospital hyperglycemia in hospitalized patients with acute heart failure: results of the IN-HF (Italian Network on Heart Failure) Outcome registry. Int J Cardiol 203:587–593PubMedCrossRef
54.
Zurück zum Zitat Oliva F, Mortara A, Cacciatore G et al (2012) Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. Eur J Heart Fail 14:1208–1217PubMedCrossRef Oliva F, Mortara A, Cacciatore G et al (2012) Acute heart failure patient profiles, management and in-hospital outcome: results of the Italian Registry on Heart Failure Outcome. Eur J Heart Fail 14:1208–1217PubMedCrossRef
55.
Zurück zum Zitat Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, Nodari S, Konstam M, Swedberg K, Maggioni AP, Zannad F, Bonow RO, Gheorghiade M (2013) EVEREST investigators. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 15:194–202 Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, Nodari S, Konstam M, Swedberg K, Maggioni AP, Zannad F, Bonow RO, Gheorghiade M (2013) EVEREST investigators. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 15:194–202
56.
Zurück zum Zitat Museedi AS, Alshami A, Douedi S et al (2021) Predictability of inpatient mortality of different comorbidities in both types of acute decompensated heart failure: analysis of national inpatient sample. Cardiol Res 12:29–36PubMedCrossRef Museedi AS, Alshami A, Douedi S et al (2021) Predictability of inpatient mortality of different comorbidities in both types of acute decompensated heart failure: analysis of national inpatient sample. Cardiol Res 12:29–36PubMedCrossRef
57.
Zurück zum Zitat Scrutinio D, Guida P, Passantino A et al (2018) Female gender and mortality risk in decompensated heart failure. Eur J Intern Med 51:34–40PubMedCrossRef Scrutinio D, Guida P, Passantino A et al (2018) Female gender and mortality risk in decompensated heart failure. Eur J Intern Med 51:34–40PubMedCrossRef
58.
Zurück zum Zitat Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL (2014) Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J 35:1284–1293PubMedCrossRef Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL (2014) Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J 35:1284–1293PubMedCrossRef
59.
Zurück zum Zitat Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, van Eck JWM, Heerspink HJL, Voors AA (2020) Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 22:713–722PubMedCrossRef Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A, van Eck JWM, Heerspink HJL, Voors AA (2020) Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 22:713–722PubMedCrossRef
60.
Zurück zum Zitat Tamaki S, Yamada T, Watanabe T et al (2021) Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study. Circ Heart Fail 14(3):e007048 Tamaki S, Yamada T, Watanabe T et al (2021) Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study. Circ Heart Fail 14(3):e007048
Metadaten
Titel
Prognostic impact of diabetes in chronic and acute heart failure
verfasst von
Stefano Ghio
Valentina Mercurio
Andrea Attanasio
Gaetano Asile
Carlo Gabriele Tocchetti
Stefania Paolillo
Publikationsdatum
22.11.2021
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 3/2023
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-021-10193-8

Weitere Artikel der Ausgabe 3/2023

Heart Failure Reviews 3/2023 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.